Deutsche Bank Comments On ABBV’s Humira Following Meeting With Momenta
In a research report published Tuesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on AbbVie (NYSE:ABBV) with an $80 price target, after hosting MNTA at DB’s BioFEST Conference in Boston.
Karnauskas noted, “Momenta could potentially get clarity on the FDA’s view about their interchangeability strategy by late 2015/2016. If the FDA agrees with their strategy, this would potentially read negatively for Humira.”
The analyst continued, “On the other hand, the company noted that the branded manufacturer would get to review their BLA for any IP infringement issues. This process could potentially delay the launch of the first biosimilar. This could potentially read positive for AbbVie.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Robyn Karnauskas has a total average return of 14.0% and a 73.8% success rate. Karnauskas has a 7.9% average return when recommending ABBV, and is ranked #139 out of 3391 analysts.